Results 161 to 170 of about 106,595 (265)

Cefdinir reprograms Gram‐positive bacteria to synergize with lysozyme against superbugs

open access: yesmLife, EarlyView.
Abstract Multidrug‐resistant (MDR) bacteria pose a critical global health threat, urgently requiring solutions. Cefdinir, the highest‐selling third‐generation cephalosporin but one now facing clinical obsolescence due to escalating resistance, is conventionally classified as a nascent cell wall synthesis inhibitor.
Qi Zhang   +6 more
wiley   +1 more source

Lipodystrophy and adipose tissue recovery are mediated by the Wnt/lipogenesis axis during skin fibrosis

open access: yesThe Journal of Pathology, EarlyView.
Abstract Acquired lipodystrophy in the dermal white adipose tissue (DWAT) is an early phenotype of skin fibrosis, followed by the accumulation of extracellular matrix (ECM). Lipodystrophy syndromes are estimated to affect 1 in 20,000 people and are associated with metabolic comorbidities.
Suneeti R Madhavan   +10 more
wiley   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

open access: yesPediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil   +2 more
wiley   +1 more source

Evidence map and gap analysis of metabolic change in pediatric growth hormone deficiency treated with growth hormone

open access: yesPediatric Investigation, EarlyView.
This evidence map of 63 studies (n = 6158) showed growth hormone therapy in children with growth hormone deficiency has neutral glucose effects, mixed lipid outcomes, potential benefits for bone mineral density, bone mineral content, and parathyroid hormone, but generally no impact on thyroid function, body composition, or body mass index.
Wei Wu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy